淋巴水肿相关共病与治疗缺口:基于BHI理赔数据库的分析
基于Blue Health Intelligence理赔数据库,纳入26,902例淋巴水肿患者,分析其共病分布及治疗率。乳腺癌是最常见共病(32.1%),治疗率94.2%;静脉性溃疡为非癌最常见共病(9.6%),治疗率仅81.7%。相当比例癌症相关淋巴水肿患者未获得适当治疗。
要点
- 乳腺癌是淋巴水肿最常见共病(32.1%),治疗率94.2%。
- 静脉性溃疡为非癌最常见共病(9.6%),治疗率仅81.7%。
- 黑色素瘤(2.1%)和前列腺癌(0.7%)共病治疗率分别为75%和82%。
核心结论
- 相当比例癌症相关淋巴水肿患者未接受适当治疗。
- 晚期静脉疾病作为淋巴水肿共病常未被治疗,存在治疗缺口。
研究设计与样本
- 回顾性分析Blue Health Intelligence研究数据库理赔数据。
- 研究样本为26,902例淋巴水肿患者,索引日期前后12个月 continuous 医疗福利。
- 数据年份为2012至2016年完整年度。
主要发现
- 乳腺癌共病淋巴水肿患者中32.1%接受任何治疗的比例为94.2%。
- 黑色素瘤共病淋巴水肿患者占2.1%,接受任何治疗的比例为75%。
- 前列腺癌共病淋巴水肿患者占0.7%,接受任何治疗的比例为82%。
- 静脉性溃疡共病淋巴水肿患者占9.6%,接受任何治疗的比例为81.7%。
关键数值与推荐
- 任何治疗定义为接受手法淋巴引流、物理治疗、压力衣物或气压治疗装置。
临床怎么用
- 临床应关注淋巴水肿患者共病筛查,尤其静脉性溃疡患者。
- 对癌症相关淋巴水肿患者应评估治疗是否充分,减少治疗缺口。
局限性
- 基于商业理赔数据,可能遗漏未就诊或未编码的淋巴水肿患者。
- 治疗定义限于特定项目,可能未涵盖所有治疗方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymphedema (LE) has been called the forgotten vascular disease, given such scant knowledge about LE-associated comorbidities or causes. Such knowledge of the comorbidities and treatment of LE may assist in diagnostic decisions and health care planning. METHODS: To determine the proportion of LE patients with various LE-associated comorbidities as well as the rate of associated treatment, deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative claims from the Blue Health Intelligence (BHI) research database (165 million Blue Cross Blue Shield members) were queried. We analyzed a BHI study sample of 26,902 patients with LE who had been enrolled with continuous medical benefits for 12 months before and after the index date for the complete years 2012 through 2016. Patients were first identified by comorbidity and then grouped into those receiving no treatment for LE and those receiving any treatment for LE. Any treatment was defined as receiving manual lymphatic drainage, physical therapy, compression garments, or a pneumatic compression device. The purpose of this study was to determine the proportion of LE patients comorbid with various known LE-associated conditions and the treatment rates of LE patients with each comorbidity. RESULTS: Among the 84,579,269 BHI patients enrolled during the study window, 81,366 patients were identified with LE. From this LE group, our study focused on the 26,902 patients who were enrolled with continuous medical and pharmacy benefits for 12 months before and after the index date. Among these 26,902 LE patients, breast cancer was the most frequent comorbidity with LE (32.1%), and these patients almost universally received any treatment (94.2%); other cancer types, such as melanoma (2.1%) and prostate cancer (0.7%), were less frequent and received any treatment less often, 75% and 82% of the time, respectively. Venous leg ulcer was the most common non-cancer-linked comorbidity for LE (9.6%), but only 81.7% of venous leg ulcer patients received any treatment for LE. CONCLUSIONS: To our knowledge, this is the largest study to date detailing the comorbidities associated with LE and LE treatment rates within each. Our findings suggest that a sizable proportion of cancer-related LE patients do not receive appropriate treatment. Furthermore, this study highlights the role of advanced venous disease as an LE comorbidity that is frequently untreated and its associated gap in treatment.
引用
- Son A, O'Donnell TF, Izhakoff J, et al. Lymphedema-associated comorbidities and treatment gap. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31248833. doi:10.1016/j.jvsv.2019.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。